Physician profile
Robert A Rizzo
NPI 1235213000
$6,701.08
in general payments reported to CMS, 2019-2025
42 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $498 · 2021: $440 · 2022: $991 · 2023: $1,200 · 2024: $1,316 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.99 |
| Education | $199.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $779.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $647.38 | 2022-2025 | Vraylar, Linzess, Creon |
| Pfizer INC. | $546.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $481.37 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $479.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $375.03 | 2019-2025 | Repatha, Otezla, Repatha |
| Philips North America LLC | $264.06 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Exact Sciences Corporation | $241.28 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $236.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $201.14 | 2019-2022 | |
| Amarin Pharma, INC. | $178.66 | 2019-2022 | |
| Astellas Pharma US INC | $167.70 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.45 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.89 | 2019-2024 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $154.39 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.